EXPLORING THE DEPTHS: UNRAVELING FGF-23 DRIVEN- HYPOPHOSPHATEMIA IN SHADOWS OF PHOSPHATURIC TUMOURS

This paper delves into the intricate realm of FGF23-induced hypophosphatemia secondary to a concealed phosphaturic tumor, shedding light on a rare yet clinically significant phenomenon. With only a limited number of reported cases worldwide, this study navigates the diagnostic challenges posed by the elusive nature of these tumors, emphasizing the importance of considering genetic etiologies.The research elucidates the pivotal role of FGF23, identified as the primary causative hormone, in orchestrating hypophosphatemia through phosphaturia. Diagnostic hurdles arising from the tumors' small size and concealed locations are addressed, with a spotlight on advanced imaging modalities such as MRI, FDG-PET scan, and 68 Ga-DOTA-TOC-PET CT scan. Recent insights into the direct impact of elevated FGF23 levels on bone health are explored, unraveling the complex interplay between FGF23, soluble Klotho, and the bone mineralization process. The study probes the ambiguity surrounding whether hypophosphatemia alone is accountable for the observed osteomalacia.This comprehensive analysis not only deepens our understanding of FGF23-induced hypophosphatemia but also underscores the necessity for heightened clinical awareness, advanced diagnostic techniques, and a multidisciplinary approach in managing patients presenting with these challenging conditions.